Surviving the Blockbuster Syndrome

See allHide authors and affiliations

Science  19 Mar 2004:
Vol. 303, Issue 5665, pp. 1796-1799
DOI: 10.1126/science.303.5665.1796

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


New technologies have sent drug company R&D costs soaring, but with no corresponding rise as yet in the number of new drugs. Executives are talking about mergers, reorganization, and other ways to kick-start their production engines.